CoChat

Transforming Cancer Prevention through Precision Medicine and Immune-oncology

Open access
Kensler, Thomas W., Spira, Avrum, Garber, Judy E., Szabo, Eva, Lee, J. Jack, Dong, Zigang, Dannenberg, Andrew J., Hait, William N., Blackburn, Elizabeth, Davidson, Nancy E., Foti, Margaret, Lippman, Scott M. · 2016 · Cancer Prevention Research
Cited by 154

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

We have entered a transformative period in cancer prevention (including early detection). Remarkable progress in precision medicine and immune-oncology, driven by extraordinary recent advances in genome-wide sequencing, big-data analytics, blood-based technologies, and deep understanding of the tumor immune microenvironment (TME), has provided unprecedented possibilities to study the biology of premalignancy. The pace of research and discovery in precision medicine and immunoprevention has been astonishing and includes the following clinical firsts reported in 2015: driver mutations detected in circulating cell-free DNA in patients with premalignant lesions (lung); clonal hematopoiesis shown to be a premalignant state; molecular selection in chemoprevention randomized controlled trial (RCT; oral); striking efficacy in RCT of combination chemoprevention targeting signaling pathway alterations mechanistically linked to germline mutation (duodenum); molecular markers for early detection validated for lung cancer and showing promise for pancreatic, liver, and ovarian cancer. Identification of HPV as the essential cause of a major global cancer burden, including HPV16 as the single driver of an epidemic of oropharyngeal cancer in men, provides unique opportunities for the dissemination and implementation of public health interventions. Important to immunoprevention beyond viral vaccines, genetic drivers of premalignant progression were associated with increasing immunosuppressive TME; and Kras vaccine efficacy in pancreas genetically engineered mouse (GEM) model required an inhibitory adjuvant (Treg depletion). In addition to developing new (e.g., epigenetic) TME regulators, recent mechanistic studies of repurposed drugs (aspirin, metformin, and tamoxifen) have identified potent immune activity. Just as precision medicine and immune-oncology are revolutionizing cancer therapy, these approaches are transforming cancer prevention. Here, we set out a brief agenda for the immediate future of cancer prevention research (including a “Pre-Cancer Genome Atlas” or “PCGA”), which will involve the inter-related fields of precision medicine and immunoprevention – pivotal elements of a broader domain of personalized public health. Cancer Prev Res; 9(1); 2–10. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1940-6207.capr-15-0406

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 154

Metadata

Authors
Kensler, T. W., Spira, A., Garber, J. E., Szabo, E., Lee, J. J., Dong, Z., Dannenberg, A. J., Hait, W. N., Blackburn, E., Davidson, N. E., Foti, M., & Lippman, S. M.
Venue
Cancer Prevention Research
Published
2016-01-01
Volume
9
Issue
1
Pages
2-10
ISSN
  • 1940-6207 (ISSN-L)
  • 1940-6215
OpenAlex
W2224030228
Cited by
154
References
19
FWCI
10.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transforming Cancer Prevention through Precision Medicine and Immune-oncology. https://app.cochat.ai/papers/10.1158/1940-6207.capr-15-0406
The paper
Kensler, T. W., Spira, A., Garber, J. E., Szabo, E., Lee, J. J., Dong, Z., Dannenberg, A. J., Hait, W. N., Blackburn, E., Davidson, N. E., Foti, M., & Lippman, S. M. (2016). Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-15-0406

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.